© The Author 2006. Published by Oxford University Press.
ARTICLE |
Antileukemic Activity of Shepherdin and Molecular Diversity of Hsp90 Inhibitors
Affiliations of authors: Departments of Cancer Biology (BG, JP, CMR, DSG, DCA) and Medicine (BG, PAL) and the Cancer Center, University of Massachusetts Medical School, Worcester, MA; Departments of Blood and Marrow Transplantation (BZC, MA) and Leukemia (MA), Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; Istituto di Chimica del Riconoscimento Molecolare, Milano, Italy (MM, GC); Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy (MM)
Correspondence to: Dario C. Altieri, MD, University of Massachusetts Medical School, LRB428, 364 Plantation Street, Worcester, MA 01605 (e-mail: dario.altieri{at}umassmed.edu).
Background: Heat shock protein 90 (Hsp90) is a molecular chaperone that is involved in signaling pathways for cell proliferation, survival, and cellular adaptation. Inhibitors of Hsp90 are being examined as cancer therapeutic agents, but the molecular mechanism of their anticancer activity is still unclear. We investigated Hsp90 as a therapeutic target for acute myeloid leukemia (AML) by use of the Hsp90 inhibitor shepherdin (a novel peptidyl antagonist of the interaction between Hsp90 and survivin, which is a regulator of cell proliferation and cell viability in cancer). Methods: We studied protein interactions by molecular dynamics simulations and conducted competition experiments by use of enzyme-linked immunosorbent assay (ELISA). Shepherdin[79–83], a novel variant carrying the survivin sequence from Lys-79 through Gly-83, or its scrambled peptide was made permeable to cells by adding the antennapedia helix III carrier sequence. Apoptosis, Hsp90 client protein expression, and mitochondrial dysfunction were evaluated in AML types (myeloblastic, monocytic, and chronic myelogenous leukemia in blast crisis), patient-derived blasts, and normal mononuclear cells. Effects of shepherdin on tumor growth were evaluated in AML xenograft tumors in mice (n = 6). Organ tissues were examined histologically. Results: Shepherdin[79–83] bound to Hsp90, inhibited formation of the survivin–Hsp90 complex, and competed with ATP binding to Hsp90. Cell-permeable shepherdin[79–83] induced rapid (within 30 minutes) and complete (with concentrations inducing 50% cell death of 24–35 µM) killing of AML types and blasts, but it did not affect normal mononuclear cells. Shepherdin[79–83] made contact with unique residues in the ATP pocket of Hsp90 (Ile-96, Asp-102, and Phe-138), did not increase Hsp70 levels in AML cells, disrupted mitochondrial function within 2 minutes of treatment, and eliminated the expression of Hsp90 client proteins. Shepherdin[79–83] abolished growth of AML xenograft tumors (mean of control group = 1698 mm3 and mean of treated group = 232 mm3; difference = 1466 mm3, 95% confidence interval = 505.8 to 2426; P = .008) without systemic or organ toxicity and inhibited Hsp90 function in vivo. Conclusions: Shepherdin is a novel Hsp90 inhibitor with a unique mechanism of anticancer activity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. KOGA, K. KIHARA, and L. NECKERS Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat-shock Protein 90 Anticancer Res, March 1, 2009; 29(3): 797 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Colombo, G. Morra, M. Meli, and G. Verkhivker Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution PNAS, June 10, 2008; 105(23): 7976 - 7981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Oh, J. K. Woo, Y. D. Yazici, J. N. Myers, W.-Y. Kim, Q. Jin, S. S. Hong, H.-J. Park, Y.-G. Suh, K.-W. Kim, et al. Structural Basis for Depletion of Heat Shock Protein 90 Client Proteins by Deguelin J Natl Cancer Inst, June 20, 2007; 99(12): 949 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pennati, M. Folini, and N. Zaffaroni Targeting survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis, June 1, 2007; 28(6): 1133 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ferrario, N. Rucker, S. Wong, M. Luna, and C. J. Gomer Survivin, a Member of the Inhibitor of Apoptosis Family, Is Induced by Photodynamic Therapy and Is a Target for Improving Treatment Response Cancer Res., May 15, 2007; 67(10): 4989 - 4995. [Abstract] [Full Text] [PDF]
|
|